DRR168521
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.450
- MYC_TARGETS_V1+0.320
- OXIDATIVE_PHOSPHORYLATION+0.260
- TGF_BETA_SIGNALING+0.260
- UNFOLDED_PROTEIN_RESPONSE+0.260
- ANDROGEN_RESPONSE+0.210
- ANGIOGENESIS+0.210
- IL6_JAK_STAT3_SIGNALING+0.210
- INTERFERON_ALPHA_RESPONSE+0.200
- UV_RESPONSE_DN+0.190
Top 10 suppressed
- E2F_TARGETS-0.220
- APICAL_SURFACE-0.210
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.210
- WNT_BETA_CATENIN_SIGNALING-0.210
- KRAS_SIGNALING_DN-0.200
- MYOGENESIS-0.190
- G2M_CHECKPOINT-0.160
- CHOLESTEROL_HOMEOSTASIS-0.150
- INFLAMMATORY_RESPONSE-0.100
- BILE_ACID_METABOLISM-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R191 | — | — | 0.713 |
| 2 | DRR168598 | — | — | 0.695 |
| 3 | MNG928 | — | — | 0.684 |
| 4 | SJEPD030097_D1.RNA-Seq | EPN | Myxopapillary EPN | 0.676 |
| 5 | BS_4NWHYH53 | Supratentorial Ependymoma | — | 0.670 |
| 6 | BS_N210XMKR | low-grade glioma | — | 0.667 |
| 7 | BS_NRFQEQKP | low-grade glioma | — | 0.665 |
| 8 | SRR934985 | — | — | 0.659 |
| 9 | TCGA-CV-A6K2-01A-11R-A31N-07 | — | — | 0.659 |
| 10 | MNG1276 | — | — | 0.658 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.450 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.260 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.190 | Inavolisib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.140 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.110 | Idelalisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |